Your browser doesn't support javascript.
loading
Herbal Medicine Yukgunja-Tang for Functional Dyspepsia: A Protocol for a Randomized, Controlled, Multicenter Clinical Trial.
Lee, Boram; Ha, Na-Yeon; Park, Hyo-Ju; Kim, Ae-Ran; Kwon, O-Jin; Cho, Jung-Hyo; Shin, Seon Mi; Kim, Jinsung; Yang, Changsop.
Afiliação
  • Lee B; KM Science Research Division, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea.
  • Ha NY; Division of Digestive Diseases, Department of Internal Korean Medicine, Kyung Hee University Medical Center, Seoul 02447, Republic of Korea.
  • Park HJ; Clinical Research Coordinating Team, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea.
  • Kim AR; Clinical Research Coordinating Team, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea.
  • Kwon OJ; KM Science Research Division, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea.
  • Cho JH; Department of Internal Medicine, Daejeon Korean Medicine Hospital of Daejeon University, Daejeon 35235, Republic of Korea.
  • Shin SM; Department of Internal Medicine, College of Korean Medicine, Semyung University, Jecheon-si 27136, Republic of Korea.
  • Kim J; Department of Gastroenterology, Kyung Hee University College of Korean Medicine, Kyung Hee University Medical Center, Seoul 02447, Republic of Korea.
  • Yang C; KM Science Research Division, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea.
Healthcare (Basel) ; 11(10)2023 May 17.
Article em En | MEDLINE | ID: mdl-37239742
ABSTRACT
The herbal medicine Yukgunja-tang has been widely used for the treatment of functional dyspepsia (FD) in the clinical setting of East Asian traditional medicine. This paper presents a protocol for a randomized, assessor-blind, controlled, multicenter, three-arm parallel clinical trial comparing the effectiveness, safety, and cost-effectiveness of Yukgunja-tang with Pyeongwi-san and usual care. A total of 140 participants with Rome IV-diagnosed FD will be randomly assigned to either the Yukgunja-tang (n = 56), Pyeongwi-san (n = 56), or usual care (n = 28) groups. All participants will be educated on dietary guidelines for FD patients. Participants in the Yukgunja-tang and Pyeongwi-san groups will take investigational products for 6 weeks. All participants will be assessed for clinical parameters at weeks 0, 3, 6, 9, and 24. The primary outcome will be measured on the total dyspepsia symptom scale, and the secondary outcome will include the single dyspepsia symptom scale, overall treatment effect, the visual analog scale for dyspepsia, FD-related quality of life, hospital anxiety and depression scale, EuroQol-5 dimension, pattern identification, and serum levels of acyl-ghrelin and deacyl-ghrelin. Adverse events and laboratory tests will be monitored for safety assessment. The results will provide evidence of the effectiveness, safety, and cost-effectiveness of Yukgunja-tang in the treatment of FD.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline Aspecto: Patient_preference Idioma: En Revista: Healthcare (Basel) Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline Aspecto: Patient_preference Idioma: En Revista: Healthcare (Basel) Ano de publicação: 2023 Tipo de documento: Article